AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36525340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 0
Study 36525340 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Number of subjects: 0
Study 36525340 — intervention group
Group type: COMPARATOR
Intervention: Mild cases of conjunctivitis (dupilumab and tralokinumab)
Number of subjects: 0
Study 36525340 — intervention group
Group type: COMPARATOR
Intervention: Severe cases of conjunctivitis (dupilumab and tralokinumab)
Number of subjects: 0
Study 36525381 — intervention group
Group type: EXPERIMENTAL
Intervention: E-health (4-month subscription to the online Goalistics Chronic Pain Management Program)
Number of subjects: 402
Study 36525381 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 402
Study 36525405 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended contingency management (CM) intervention with escalating incentives contingent on abstinence
Number of subjects: 90
Study 36525405 — intervention group
Group type: COMPARATOR
Intervention: Control group with fixed incentives for attending study visits
Number of subjects: 90
Study 36525405 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended CM intervention
Number of subjects: 90
Study 36525405 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 36525493 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-EGFR antibody combined with neoadjuvant chemotherapy
Number of subjects: 0
Study 36525493 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-EGFR antibody
Number of subjects: 0
Study 36525540 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO-PCI in ACS patients
Number of subjects: 558
Study 36525540 — intervention group
Group type: COMPARATOR
Intervention: CTO-PCI in non-ACS patients
Number of subjects: 558
Study 36525544 — intervention group
Group type: EXPERIMENTAL
Intervention: Life's Simple 7 (LS7) assessment of cardiovascular health (CVH)
Number of subjects: 735
Study 36525606 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding hydroxychloroquine and sulfasalazine for the first 12 weeks and then discontinuing TNFi for the following 48 weeks (Group A)
Number of subjects: 67
Study 36525606 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining TNFi and MTX for 60 weeks (Group B)
Number of subjects: 67
Study 36525606 — intervention group
Group type: COMPARATOR
Intervention: Maintaining TNFi and MTX for the first 12 weeks and then discontinuing TNFi for the following 48 weeks (Group C)
Number of subjects: 67
Study 36525606 — intervention group
Group type: COMPARATOR
Intervention: Comparative analysis of Group A and Group B vs Group C
Number of subjects: 67
Study 36525610 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX
Number of subjects: 315
Study 36525610 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up
Number of subjects: 315
Study 36525620 — intervention group
Group type: EXPERIMENTAL
Intervention: TA (Treatment A)
Number of subjects: 1152
Study 36525620 — intervention group
Group type: COMPARATOR
Intervention: CO (Control)
Number of subjects: 1152
Study 36525620 — intervention group
Group type: EXPERIMENTAL
Intervention: Other ablation treatments
Number of subjects: 1152
Study 36525627 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid intervention combining Enhanced Milieu Teaching (EMT) and Joint Attention, Symbolic Play, Engagement, and Regulation (JASPER)
Number of subjects: 120
Study 36525627 — intervention group
Group type: COMPARATOR
Intervention: Behavior management control condition
Number of subjects: 120
Study 36525653 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 455
Study 36525653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteroides abundance
Number of subjects: 455
Study 36525653 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha diversity
Number of subjects: 455
Study 36525653 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta diversity
Number of subjects: 455
Study 36525797 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDPass (50 ml of ONS four times per day with medication rounds)
Number of subjects: 204
Study 36525797 — intervention group
Group type: COMPARATOR
Intervention: Conventional ONS administration (between meals)
Number of subjects: 204
Study 36525797 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDPass
Number of subjects: 204
Study 36525797 — intervention group
Group type: COMPARATOR
Intervention: Conventional ONS administration
Number of subjects: 204
Study 36525851 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) + Fitbit
Number of subjects: 340
Study 36525851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) + Fitbit
Number of subjects: 340
Study 36525851 — intervention group
Group type: COMPARATOR
Intervention: Fitbit only
Number of subjects: 340
Study 36525985 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg (two capsules on day 1 followed by one capsule daily for 4 days)
Number of subjects: 499
Study 36525985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching capsules)
Number of subjects: 499
Study 36525985 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 499
Study 36525985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 499
Study 36526251 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive, semistructured spiritual care intervention delivered by chaplains
Number of subjects: 192
Study 36526251 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 192
Study 36526263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ)
Number of subjects: 0
Study 36526263 — intervention group
Group type: EXPERIMENTAL
Intervention: FOP-PFQ scores
Number of subjects: 0
Study 36526263 — intervention group
Group type: EXPERIMENTAL
Intervention: FOP-PFQ
Number of subjects: 0
Study 36526308 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based joint hypermobility assessment using smartphone camera
Number of subjects: 0
Study 36526308 — intervention group
Group type: COMPARATOR
Intervention: Clinical-grade goniometer measurements
Number of subjects: 0
Study 36526425 — intervention group
Group type: EXPERIMENTAL
Intervention: Language therapy for 6 weeks
Number of subjects: 93
Study 36526425 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced brain age (n = 47)
Number of subjects: 93
Study 36526425 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy outcome scores
Number of subjects: 93
Study 36526481 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dexamethasone (1 mg/kg)
Number of subjects: 157
Study 36526481 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 157
Study 36526480 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation exercises
Number of subjects: 32
Study 36526480 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress balls
Number of subjects: 32
Study 36526480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 36526521 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg daily) for 6 weeks prior to nephrectomy
Number of subjects: 25
Study 36526521 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg daily)
Number of subjects: 25
Study 36526521 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of circulating biomarkers
Number of subjects: 25
Study 36526521 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of circulating biomarkers
Number of subjects: 25
Study 36526577 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomographic (PET) and computed tomographic (CT) imaging using a novel glycoprotein IIb/IIIa receptor antagonist-based radiotracer
Number of subjects: 0
Study 36526577 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without acute myocardial infarction)
Number of subjects: 0
Study 36526640 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Number of subjects: 0
Study 36526640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36526739 — intervention group
Group type: EXPERIMENTAL
Intervention: Night Shift Fasting (NSF)
Number of subjects: 10
Study 36526739 — intervention group
Group type: EXPERIMENTAL
Intervention: Night Shift Eating (NSE)
Number of subjects: 10
Study 36526739 — intervention group
Group type: COMPARATOR
Intervention: Nighttime Sleep (NS)
Number of subjects: 10
Study 36526794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 212
Study 36526794 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac (0.5 mg/kg)
Number of subjects: 212
Study 36526796 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg BID
Number of subjects: 0
Study 36526796 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg BID
Number of subjects: 0
Study 36526796 — intervention group
Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 0
Study 36526796 — intervention group
Group type: COMPARATOR
Intervention: methotrexate
Number of subjects: 0
Study 36526796 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 36526815 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone treatment (Cohort 1, n=14)
Number of subjects: 58
Study 36526815 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Cohort 2, n=15)
Number of subjects: 58
Study 36526815 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of tumours
Number of subjects: 58
Study 36526826 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month physical activity intervention (BEAT Cancer)
Number of subjects: 222
Study 36526826 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 222
Study 36526846 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainers (VFR) covering all erupted teeth in the maxilla and first premolar to first premolar in the mandible.
Number of subjects: 104
Study 36526846 — intervention group
Group type: COMPARATOR
Intervention: Bonded canine-to-canine retainers with VFR in the maxilla covering all erupted teeth.
Number of subjects: 104
Study 36526846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both retention protocols (VFR and bonded retainers).
Number of subjects: 104
Study 36526846 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainers (VFR).
Number of subjects: 104
Study 36526898 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36526924 — intervention group
Group type: EXPERIMENTAL
Intervention: TBR Neurofeedback (NF)
Number of subjects: 142
Study 36526924 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 142
Study 36526937 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 109
Study 36526937 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 109
Study 36526947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 82
Study 36526947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin FDC 50/850 mg
Number of subjects: 82
Study 36526947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin FDC 50/1000 mg
Number of subjects: 82
Study 36526961 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation
Number of subjects: 18
Study 36526961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 36527018 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care intervention for panic-related anxiety
Number of subjects: 212
Study 36527018 — intervention group
Group type: COMPARATOR
Intervention: Screening for panic attacks and panic disorder (Control)
Number of subjects: 212
Study 36527025 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg RT234
Number of subjects: 86
Study 36527025 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg RT234
Number of subjects: 86
Study 36527073 — intervention group
Group type: EXPERIMENTAL
Intervention: AATD individuals with PI*ZZ genotype
Number of subjects: 1044
Study 36527073 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with impairment in FEV1(%) alone
Number of subjects: 1044
Study 36527073 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with impairment in KCO(%) alone
Number of subjects: 1044
Study 36527073 — intervention group
Group type: EXPERIMENTAL
Intervention: AATD individuals with advanced age, male sex, exacerbations, increased blood platelets and neutrophils, lower AAT serum levels
Number of subjects: 1044
Study 36527074 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation services (physical and cognitive domains)
Number of subjects: 1379
Study 36527074 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation services at three or six months
Number of subjects: 1379
Study 36527074 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of transition of care (TOC) pathways
Number of subjects: 1379
Study 36527074 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-morbid psychiatric problems
Number of subjects: 1379
Study 36527074 — intervention group
Group type: EXPERIMENTAL
Intervention: Being male and having more than 13 years of education
Number of subjects: 1379
Study 36527074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustaining major trauma
Number of subjects: 1379
Study 36527074 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in Southern and Eastern European regions
Number of subjects: 1379
Study 36527120 — intervention group
Group type: EXPERIMENTAL
Intervention: Savings group (access to a savings account with lottery-based incentives, savings goals/strategies, and text message reminders)
Number of subjects: 1500
Study 36527120 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic health education)
Number of subjects: 1500
Study 36527143 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bolus of 100,000 IU with 10,000 IU/week of vitamin D
Number of subjects: 34
Study 36527143 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 34
Study 36527262 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone (VMP)
Number of subjects: 144
Study 36527262 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 144
Study 36527367 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of cross-linked hyaluronic acid (HANOX-M-XL)
Number of subjects: 51
Study 36527386 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 456906 (subcutaneous glucagon-like peptide-1 receptor/glucagon receptor dual agonist)
Number of subjects: 149
Study 36527513 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cells expanded ex vivo with K-562-41BBL-mbIL21 cell line
Number of subjects: 16
Study 36527520 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA)
Number of subjects: 63
Study 36527520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham Acupuncture (SA)
Number of subjects: 63
Study 36527520 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 63
Study 36527570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF) assessed by a 10-min running test
Number of subjects: 1985
Study 36527570 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular fitness assessed by sit-ups test
Number of subjects: 1985
Study 36527570 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular fitness assessed by handgrip test
Number of subjects: 1985
Study 36527570 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive strength in the lower body
Number of subjects: 1985
Study 36527702 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended CINV (≥3 days) in C1
Number of subjects: 402
Study 36527702 — intervention group
Group type: EXPERIMENTAL
Intervention: Short CINV (1-2 days) in C1
Number of subjects: 402
Study 36527702 — intervention group
Group type: EXPERIMENTAL
Intervention: CINV duration monitoring and augmented antiemetic prophylaxis
Number of subjects: 402
Study 36527702 — intervention group
Group type: COMPARATOR
Intervention: Complete response (CR) in C1
Number of subjects: 402
Study 36527702 — intervention group
Group type: COMPARATOR
Intervention: Treatment failure (TF) in C1
Number of subjects: 402
Study 36527859 — intervention group
Group type: EXPERIMENTAL
Intervention: FOREST intervention
Number of subjects: 168
Study 36527955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive and exercise training (CT&E)
Number of subjects: 37
Study 36527955 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training alone (CT)
Number of subjects: 37
Study 36528005 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stress
Number of subjects: 471
Study 36528005 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorer sleep quality
Number of subjects: 471
Study 36528005 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorer well-being
Number of subjects: 471
Study 36528005 — intervention group
Group type: EXPERIMENTAL
Intervention: ACWR below 0.8 or above 1.3
Number of subjects: 471
Study 36528035 — intervention group
Group type: EXPERIMENTAL
Intervention: KRd plus autologous stem-cell transplantation (ASCT)
Number of subjects: 477
Study 36528035 — intervention group
Group type: EXPERIMENTAL
Intervention: KRd plus ASCT
Number of subjects: 477
Study 36528039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral favipiravir plus standard care (1800 mg twice daily for 1 day; 800 mg twice daily for 9 days)
Number of subjects: 499
Study 36528039 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 499
Study 36528039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral favipiravir plus standard care (in patients younger than 60 years)
Number of subjects: 499
Study 36528039 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (in patients younger than 60 years)
Number of subjects: 499
Study 36528039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral favipiravir plus standard care
Number of subjects: 499
Study 36528053 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine and medication delivery service (TMDS) called 'MotoMeds'
Number of subjects: 391
Study 36528055 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive human milk diet
Number of subjects: 107
Study 36528055 — intervention group
Group type: COMPARATOR
Intervention: Control group (mixed human and bovine diet)
Number of subjects: 107
Study 36528108 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell RNA sequencing in decidual tissues of missed-abortion group
Number of subjects: 34
Study 36528108 — intervention group
Group type: COMPARATOR
Intervention: Single-cell RNA sequencing in decidual tissues of elective terminations
Number of subjects: 34
Study 36528108 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of senescent SCs and chromosomal abnormalities
Number of subjects: 34
Study 36528108 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of HLA-KIR interaction
Number of subjects: 34
Study 36528108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothesis on DIO2 marker of senescent SCs
Number of subjects: 34
Study 36528113 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including advanced notification, mailed fecal immunochemical test (FIT) kits and reminders
Number of subjects: 9699
Study 36528113 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 9699
Study 36528115 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass index (FMI)
Number of subjects: 356
Study 36528115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body mass index (LBMI)
Number of subjects: 356
Study 36528115 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 356
Study 36528115 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant FMI above the median with BMI below
Number of subjects: 356
Study 36528115 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI above the median with FMI below
Number of subjects: 356
Study 36528340 — intervention group
Group type: EXPERIMENTAL
Intervention: 165-SNP polygenic risk score (PRS) developed with PLINK
Number of subjects: 785
Study 36528340 — intervention group
Group type: COMPARATOR
Intervention: Previously-published PRS
Number of subjects: 785
Study 36528376 — intervention group
Group type: EXPERIMENTAL
Intervention: Emraclidine 30 mg once daily
Number of subjects: 130
Study 36528376 — intervention group
Group type: EXPERIMENTAL
Intervention: Emraclidine 20 mg twice daily
Number of subjects: 130
Study 36528376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 36528376 — intervention group
Group type: EXPERIMENTAL
Intervention: Emraclidine (combined groups)
Number of subjects: 130
Study 36528376 — intervention group
Group type: EXPERIMENTAL
Intervention: Emraclidine groups
Number of subjects: 130
Study 36528443 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP∼T vaccine (Hexyon™, Sanofi) administered at 8, 12, 16 weeks and booster at 13 months (preterm) or 15 months (term)
Number of subjects: 332
Study 36528522 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1810631 (15 mg BID, escalating doses)
Number of subjects: 0
Study 36528522 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1810631 (escalating doses)
Number of subjects: 0
Study 36528522 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1810631
Number of subjects: 0
Study 36528547 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal protective aids
Number of subjects: 0
Study 36528590 — intervention group
Group type: EXPERIMENTAL
Intervention: Deployment of male Wolbachia-infected Ae. aegypti mosquitoes
Number of subjects: 15
Study 36528590 — intervention group
Group type: EXPERIMENTAL
Intervention: Incompatible insect technique coupled with sterile insect technique (IIT-SIT)
Number of subjects: 15
Study 36528609 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app DiaCert promoting physical activity for 3 months in addition to routine care
Number of subjects: 181
Study 36528609 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 181
Study 36528670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 34000
Study 36528670 — intervention group
Group type: COMPARATOR
Intervention: Comparator GLDs
Number of subjects: 34000